ASTRAZENECA PHARMA | NATCO PHARMA | ASTRAZENECA PHARMA/ NATCO PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 116.0 | 30.5 | 380.1% | View Chart |
P/BV | x | 35.5 | 4.3 | 818.5% | View Chart |
Dividend Yield | % | 0.0 | 0.8 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-18 |
NATCO PHARMA Mar-19 |
ASTRAZENECA PHARMA/ NATCO PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,278 | 849 | 150.5% | |
Low | Rs | 883 | 557 | 158.5% | |
Sales per share (Unadj.) | Rs | 228.4 | 573.8 | 39.8% | |
Earnings per share (Unadj.) | Rs | 10.4 | 176.0 | 5.9% | |
Cash flow per share (Unadj.) | Rs | 16.3 | 198.2 | 8.2% | |
Dividends per share (Unadj.) | Rs | 0 | 6.25 | 0.0% | |
Dividend yield (eoy) | % | 0 | 0.9 | 0.0% | |
Book value per share (Unadj.) | Rs | 98.8 | 842.7 | 11.7% | |
Shares outstanding (eoy) | m | 25.00 | 36.50 | 68.5% | |
Bonus/Rights/Conversions | - | BB | - | ||
Price / Sales ratio | x | 4.7 | 1.2 | 386.1% | |
Avg P/E ratio | x | 104.2 | 4.0 | 2,609.6% | |
P/CF ratio (eoy) | x | 66.4 | 3.5 | 1,873.1% | |
Price / Book Value ratio | x | 10.9 | 0.8 | 1,311.1% | |
Dividend payout | % | 0 | 3.6 | 0.0% | |
Avg Mkt Cap | Rs m | 27,008 | 25,660 | 105.3% | |
No. of employees | `000 | 1.4 | 5.0 | 27.4% | |
Total wages/salary | Rs m | 1,535 | 3,559 | 43.1% | |
Avg. sales/employee | Rs Th | 4,210.9 | 4,225.3 | 99.7% | |
Avg. wages/employee | Rs Th | 1,132.2 | 718.0 | 157.7% | |
Avg. net profit/employee | Rs Th | 191.1 | 1,295.9 | 14.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 5,710 | 20,945 | 27.3% | |
Other income | Rs m | 123 | 1,302 | 9.4% | |
Total revenues | Rs m | 5,833 | 22,247 | 26.2% | |
Gross profit | Rs m | 463 | 7,948 | 5.8% | |
Depreciation | Rs m | 147 | 810 | 18.2% | |
Interest | Rs m | 0 | 193 | 0.0% | |
Profit before tax | Rs m | 438 | 8,247 | 5.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 179 | 1,823 | 9.8% | |
Profit after tax | Rs m | 259 | 6,424 | 4.0% | |
Gross profit margin | % | 8.1 | 37.9 | 21.4% | |
Effective tax rate | % | 40.8 | 22.1 | 184.8% | |
Net profit margin | % | 4.5 | 30.7 | 14.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,209 | 23,472 | 13.7% | |
Current liabilities | Rs m | 2,070 | 7,287 | 28.4% | |
Net working cap to sales | % | 20.0 | 77.3 | 25.8% | |
Current ratio | x | 1.6 | 3.2 | 48.1% | |
Inventory Days | Days | 72 | 92 | 78.5% | |
Debtors Days | Days | 35 | 88 | 39.6% | |
Net fixed assets | Rs m | 790 | 18,648 | 4.2% | |
Share capital | Rs m | 50 | 365 | 13.7% | |
"Free" reserves | Rs m | 2,419 | 34,525 | 7.0% | |
Net worth | Rs m | 2,469 | 30,760 | 8.0% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 4,605 | 43,031 | 10.7% | |
Interest coverage | x | NM | 43.7 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.2 | 0.5 | 254.7% | |
Return on assets | % | 5.6 | 15.4 | 36.6% | |
Return on equity | % | 10.5 | 20.9 | 50.2% | |
Return on capital | % | 17.7 | 27.4 | 64.6% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 300 | 11,536 | 2.6% | |
Fx outflow | Rs m | 2,015 | 2,939 | 68.6% | |
Net fx | Rs m | -1,715 | 8,597 | -20.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 88 | 6,688 | 1.3% | |
From Investments | Rs m | -94 | -6,122 | 1.5% | |
From Financial Activity | Rs m | NA | -509 | 0.0% | |
Net Cashflow | Rs m | -6 | 66 | -8.6% |
Indian Promoters | % | 0.0 | 52.0 | - | |
Foreign collaborators | % | 75.0 | 1.5 | 5,102.0% | |
Indian inst/Mut Fund | % | 0.3 | 7.8 | 3.8% | |
FIIs | % | 15.7 | 16.6 | 94.4% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 9.1 | 26.0 | 35.0% | |
Shareholders | 12,856 | 25,395 | 50.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ASTRAZENECA PHARMA With: TTK HEALTHCARE ALEMBIC DR. REDDYS LAB CADILA HEALTHCARE SUVEN LIFE SCIENCES
Compare ASTRAZENECA PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets edged higher today as investors shrugged off concerns that stocks may have rallied too far too fast in the past year.
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended December 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 34.5% YoY). Sales on the other hand came in at Rs 5 bn (down 13.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More